Rex Bionics PLC Crispin Simon joins Rex Bionics as CEO
October 08 2014 - 2:01AM
RNS Non-Regulatory
TIDMRXB
Rex Bionics PLC
08 October 2014
For immediate release
Rex Bionics plc
("Rex Bionics" or the "Company")
Crispin Simon joins Rex Bionics as Chief Executive Officer
8 October 2014 Rex Bionics plc (AIM: RXB), the developer and
manufacturer of REX products: hands-free robotic exoskeletons for
use by wheelchair users, is pleased to announce that Crispin Simon
has now joined the Company as Chief Executive Officer. As announced
on 5 August 2014, Jeremy Curnock Cook has also moved to become
Deputy Chairman.
Crispin Simon has a 25-year track record in industry,
predominantly in the commercialisation of Medical Technology
products. Following a career which included NM Rothschild,
McKinsey, Rexam and Smith & Nephew, where he was latterly
President of the Endoscopy Division, Crispin was Chief Executive of
Biocompatibles International Plc ("Biocompatibles") until its sale
to BTG Plc in early 2011. At Biocompatibles, he led a team that
developed three medical products businesses: the Cardiovascular
Stent business, sold to Abbott Laboratories Inc for GBP145 million;
the Contact Lens business, sold to Cooper Industries Inc for GBP80
million and the Drug-eluting Bead business, which was sold as part
of the disposal of the whole company to BTG for GBP165 million. In
addition, GBP123 million of cash was returned to shareholders. From
2012 to October 2014, Crispin was a full time Director in the UK
Government's Department of Business, Innovation and Skills.
Crispin Simon said: "Rex Bionics' unique medical technology has
already demonstrated to me the potential it has for wheelchair
users - both from a health and quality of life perspective. We are
focused on penetrating rehabilitation centres internationally and
the device is gaining interest from many groups. I look forward to
our products making a real difference to the lives of wheelchair
users and to converting sales into significant shareholder
value."
David Macfarlane, Chairman, commented: "Crispin joins Rex
Bionics at a period of intense commercial, development and
manufacturing activity. He has an exceptional track record within
the healthcare sector and is the right person to take the company
to the next stage of its growth. On behalf of the Board and
management team I wish to thank Jeremy for his incredible vision,
leadership and drive that has enabled us to achieve as much as we
have over the recent months. We are delighted he will remain as a
member of our Board and continue his close involvement with the
business."
Jeremy Curnock Cook, Deputy Chairman, added: "I am delighted
that we have been able to attract Crispin to Rex Bionics. We are
well positioned both with our commercial activities and
operationally and I believe this is the right time for Crispin to
step in. Crispin's appointment will allow me to spend more time on
my other business activities around the world, but I fully intend
to continue to work closely with the Rex Bionics team in this next
exciting phase of the Company's development."
---
For further information please contact:
Rex Bionics Plc
Crispin Simon, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and
manufacturer of REX products, hands-free robotic exoskeletons for
use by people with mobility impairments. Founded in Auckland, New
Zealand by two robotics engineers with first-hand experience of
wheelchair users and their needs, Rex Bionics focuses on products
designed to enable wheelchair users to stand and walk autonomously
without the need for crutches or supports and is the only company
to produce hands-free walking devices for wheelchair users. Rex
Bionics' marketed products: REX Rehab and REX Personal, can be used
by people with complete spinal cord injury, but also by a much
broader potential customer base, including people with multiple
sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined
AIM with a fundraising of GBP10 million (gross) to scale up
production, distribution and marketing internationally, in order to
support growing demand for both REX products as well as developing
the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFSAFAWFLSEIS
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Aug 2023 to Aug 2024